Hypnogen

Zolpidem Tartrate, the active ingredient in Hypnogen, is a non‑benzodiazepine hypnotic presented as an oral dosage form for oral use. It is prescribed to manage insomnia, helping both sleep onset and maintenance in adult patients.

GNH USA supplies Hypnogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zolpidem Tartrate acts on the central nervous system to facilitate sleep in patients with insomnia.

- Insomnia (sleep onset): reduces the time required to fall asleep. - Insomnia (sleep maintenance): helps sustain sleep throughout the night. - Primary insomnia: improves overall sleep quality and duration.

Zolpidem Tartrate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate cranial pain. - Somnolence: excessive daytime sleepiness. - Dry mouth: reduced salivary flow. - Nausea: mild gastrointestinal upset. - Amnesia: short‑term memory gaps, especially after dosing.

Serious or Rare Side Effects: - Complex sleep behaviours: sleepwalking, sleep‑driving, or other activities performed while not fully awake. - Allergic reactions: rash, itching, or swelling. - Depression or suicidal thoughts: mood changes requiring immediate medical attention. - Respiratory depression: slowed breathing, particularly when combined with other depressants.

Zolpidem Tartrate requires careful use to minimise risks and ensure safe outcomes.

- Avoid alcohol: concurrent use can intensify sedation and respiratory depression. - Hepatic impairment: dose adjustment may be needed in patients with liver dysfunction. - Respiratory disorders: use cautiously in individuals with severe asthma or COPD. - Short‑term therapy: limit use to the shortest duration necessary to treat insomnia. - Complex sleep behaviours: monitor patients for unusual activities during sleep. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Zolpidem Tartrate can interact with several drug classes, altering its safety profile.

Major Interactions (Avoid): - CNS depressants (e.g., opioids, benzodiazepines, barbiturates): may cause profound sedation and respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase zolpidem plasma concentrations. - MAO inhibitors: risk of excessive CNS depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antidepressants (e.g., SSRIs, SNRIs): can enhance sedation. - Antihistamines: may increase drowsiness.